多西他赛联合奈达铂与多西他赛单药治疗晚期宫颈癌效果比较

Comparison of Effects of Docetaxel Combined with Nedaplatin and Single Drug of Docetaxel in the Treatment of Advanced Cervical Cancer

目的探究多西他赛联合奈达铂与多西他赛单药治疗晚期宫颈癌效果比较。方法选取94例晚期宫颈癌患者为受试对象,使用随机数字表法分为联合组与对照组各47例。对照组予以多西他赛单药治疗,联合组在其基础上联合奈达铂进行治疗。比较两组患者治疗前及治疗3个月后血清肿瘤标志物[癌抗原199(CA199)、癌胚抗原(CEA)]水平、外周血免疫指标(CD^4+、CD^8+、CD^4+/CD^8+)水平变化,比较两组患者治疗期间化疗不良反应差异,比较两组患者治疗1年后生存情况差异。结果治疗3个月后,两组患者CA199、CEA水平均较治疗前下降,且联合组低于对照组(P<0.05);两组患者CD^4+、CD^8+、CD^4+/CD^8+水平均较治疗前下降,且联合组高于对照组(P<0.05)。两组患者治疗期间化疗不良反应差异无统计学意义(P>0.05);治疗1年后联合组患者生存率高于对照组(P<0.05)。结论多西他赛联合奈达铂治疗晚期宫颈癌效果优于多西他赛单药,且对机体免疫功能影响较小,安全性较好。

Objective To explore the effects of docetaxel combined with nedaplatin and single drug of docetaxel in the treatment of advanced cervical cancer.Methods A total of 94 patients with advanced cervical cancer who were admitted to our hospital were selected as the study subjects.According to the random number table method,they were divided into combined group and control group,with 47 cases in each group.Control group was given docetaxel monotherapy while combined group was combined with nedaplatin on this basis.The levels of serum tumor markers[carcinoma antigen 199(CA199),carcinoembryonic antigen(CEA)] and peripheral blood immune indicators(CD^4+,CD^8+,CD^4+/CD^8+)were compared between the two groups before treatment and after 3 months of treatment.The differences in adverse chemotherapy reactions during treatment were compared between the two groups.The survival after 1 year of treatment was compared between the two groups.Results After 3 months of treatment,the levels of CA199 and CEA in the two groups were decreased compared with those before treatment,and the levels in combined group were lower than those in control group(all P<0.05).The levels of CD^4+,CD^8+ and CD^4+/CD^8+ in the two groups were decreased compared with those before treatment,and the levels in combined group were higher than those in control group(all P<0.05).There were no significant differences in the adverse chemotherapy reactions between the two groups during treatment(all P>0.05).The survival rate of the patients in combined group after 1 year of treatment was higher than that in control group(P<0.05).Conclusion Docetaxel combined with nedaplatin is more effective than single drug of docetaxel in the treatment of advanced cervical cancer,and it has less effect on the body’s immune function and has better safety.